Priced for Perfection.
Using AI to explain why that stock you've never heard of is up 6000%.
Moderna, Inc. (MRNA)
On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer therapy hit its endpoints in the Phase 3 INTerpath-001 melanoma trial — the first positive late-stage readout for an mRNA cancer therapy in history — and the stock closed up roughly 178% in a single session. This deep dive examines whether a company whose revenue has fallen from $19 billion to under $2 billion, whose federal contracts were terminated by an HHS openly hostile to mRNA, and which still loses roughly $780 million a quarter has genuinely earned a $70 billion valuation overnight. We break down the fundamentals behind the headline, the newly approved mFLUSIVA flu vaccine, the $2.25 billion patent settlement, the 50/50 economics Moderna shares with Merck, uniformly one-directional insider selling, the institutional split that saw Fidelity and T. Rowe Price buying while D.E. Shaw exited, and how Moderna compares to BioNTech, Pfizer, and Novavax. The catch: the announcement disclosed no hazard ratios, no effect sizes, and no survival data, and roughly a third of the move was short covering against a 13.5% short float. Read on for what the market has already priced in — and what it hasn't seen yet.
Read →
Cerebras Systems Inc. (CBRS)
Cerebras Systems (CBRS) built a computer chip the size of a dinner plate, and in May 2026 it turned that bet into the largest semiconductor IPO in history — $6.4 billion raised, a 68% first-day pop, and then a 58% slide from the high in six weeks. This deep dive unpacks what actually happened: a $25 billion contracted backlog dominated by a single OpenAI agreement that also makes OpenAI a lender and a prospective 10% shareholder, an 86% revenue concentration in two Abu Dhabi entities, and a deliberate margin collapse as the company rents its own systems back to serve demand faster. We work through the fundamentals, the wafer-scale architecture that lets Cerebras skip the HBM shortage entirely, the DOE and national-lab relationships, retail and institutional positioning including a rapidly building short base, and how CBRS compares to NVIDIA, Groq, and CoreWeave.
Corning Incorporated (GLW)
Once known mostly for Gorilla Glass and Pyrex, 175-year-old Corning (GLW) has become one of the most foundational physical-layer suppliers of the AI boom — the company that makes the optical fiber, cable, and connectivity wiring hyperscale data centers together. This deep dive unpacks the run of multibillion-dollar deals (Meta, Amazon, and an NVIDIA equity partnership) and the upgraded "Springboard" plan targeting $35–40 billion in sales by 2030, then asks whether a profitable, dividend-paying blue-chip that has risen roughly sixfold since 2023 still has room to run — or whether a triple-digit P/E, cyclical glass and solar exposure, and heavy insider selling are warning signs. We break down the fundamentals, the marquee partnerships, CHIPS Act funding and government ties, social and institutional sentiment, and how Corning stacks up against optical rivals Coherent, Lumentum, and Amphenol. The verdict: Corning is positioned to lead the optical layer of the AI buildout, but its stock has, for now, run ahead of even its improving fundamentals. Read on for the full picture.
Ouster, Inc. (OUST)
Once a SPAC-era lidar hopeful, Ouster, Inc. (OUST) has reinvented itself as a "sensing and perception for Physical AI" platform — pairing its chip-based digital lidar with cameras, AI compute, and software — and has rocketed to multi-year highs on the back of its native-color Rev8 launch, defense and smart-infrastructure wins, and a powerful regulatory tailwind. This deep dive examines whether Ouster's clean balance sheet, NDAA-compliant "trusted-supplier" moat, and 700-plus BlueCity deployments justify a stock trading near $50 at roughly 9x sales — or whether persistent losses, lumpy margins, heavy insider selling, and a freshly doubled authorized-share count are warning signs. We break down the fundamentals, the Rev8 product cycle and marquee partnerships, social and institutional sentiment, the NDAA Section 164 ban on Chinese lidar, and how Ouster stacks up against rivals Aeva, Innoviz, and China's Hesai. The verdict: Ouster is squarely aimed at where 3D perception is heading and is the best-capitalized U.S. pure-play in a protected procurement lane, but it remains a high-beta bet that has already priced in years of flawless, dilution-light execution.